BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30510249)

  • 1. Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.
    Lange T; Oh-Hohenhorst SJ; Joosse SA; Pantel K; Hahn O; Gosau T; Dyshlovoy SA; Wellbrock J; Feldhaus S; Maar H; Gehrcke R; Kluth M; Simon R; Schlomm T; Huland H; Schumacher U
    Sci Rep; 2018 Dec; 8(1):17535. PubMed ID: 30510249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An original patient-derived xenograft of prostate cancer with cyst formation.
    Yoshikawa T; Kobori G; Goto T; Akamatsu S; Terada N; Kobayashi T; Tanaka Y; Jung G; Kamba T; Ogawa O; Inoue T
    Prostate; 2016 Aug; 76(11):994-1003. PubMed ID: 27098584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
    Böckelmann LC; Freytag V; Ahlers AK; Maar H; Gosau T; Baranowsky A; Schmitz R; Pantel K; Schumacher U; Haider MT; Lange T
    Bone; 2023 Jun; 171():116741. PubMed ID: 36934984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic phenotype in CWR22 prostate cancer xenograft following castration.
    Seedhouse SJ; Affronti HC; Karasik E; Gillard BM; Azabdaftari G; Smiraglia DJ; Foster BA
    Prostate; 2016 Mar; 76(4):359-68. PubMed ID: 26642837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
    Paez-Ribes M; Man S; Xu P; Kerbel RS
    PLoS One; 2016; 11(6):e0158034. PubMed ID: 27355476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
    Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
    Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
    Linxweiler J; Körbel C; Müller A; Hammer M; Veith C; Bohle RM; Stöckle M; Junker K; Menger MD; Saar M
    Prostate; 2018 Jun; 78(9):664-675. PubMed ID: 29572953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
    Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
    Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.
    Radaelli E; Hermans E; Omodho L; Francis A; Vander Borght S; Marine JC; van den Oord J; Amant F
    PLoS One; 2015; 10(5):e0124974. PubMed ID: 25996609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
    Cyrta J; Prandi D; Arora A; Hovelson DH; Sboner A; Rodriguez A; Fedrizzi T; Beltran H; Robinson DR; Gopalan A; True L; Nelson PS; Robinson BD; Mosquera JM; Tomlins SA; Shen R; Demichelis F; Rubin MA
    J Pathol; 2022 Jul; 257(3):274-284. PubMed ID: 35220606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer.
    Guo S; Gao S; Liu R; Shen J; Shi X; Bai S; Wang H; Zheng K; Shao Z; Liang C; Peng S; Jin G
    FASEB J; 2019 Jan; 33(1):873-884. PubMed ID: 30091943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
    Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
    Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.